199 related articles for article (PubMed ID: 19100914)
1. Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen.
Bristow RE
Gynecol Oncol; 2009 Jan; 112(1):1-3. PubMed ID: 19100914
[No Abstract] [Full Text] [Related]
2. Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Kang S; Kim TJ; Seo SS; Kim BG; Bae DS; Park SY
Gynecol Oncol; 2011 Jan; 120(1):18-22. PubMed ID: 21035174
[TBL] [Abstract][Full Text] [Related]
3. Advanced cytoreductive surgery in gynecologic oncology.
Bristow RE
Gynecol Oncol; 2009 Aug; 114(2 Suppl):S1-2. PubMed ID: 19573698
[No Abstract] [Full Text] [Related]
4. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.
Harter P; Muallem ZM; Buhrmann C; Lorenz D; Kaub C; Hils R; Kommoss S; Heitz F; Traut A; du Bois A
Gynecol Oncol; 2011 Jun; 121(3):615-9. PubMed ID: 21414656
[TBL] [Abstract][Full Text] [Related]
5. [Quality control of the surgical management of advanced ovarian carcinoma].
Pomel C; Lecuru F; Rouzier R; Dauplat J; Ferron G
J Gynecol Obstet Biol Reprod (Paris); 2012 Feb; 41(1):3-5. PubMed ID: 22192233
[No Abstract] [Full Text] [Related]
6. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
[TBL] [Abstract][Full Text] [Related]
7. CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma.
Alcázar JL; Miranda D; Unanue A; Novoa E; Alemán S; Madariaga L
Int J Gynaecol Obstet; 2004 Feb; 84(2):173-4. PubMed ID: 14871524
[No Abstract] [Full Text] [Related]
8. Surgical management of women with ovarian cancer.
Cooper A; DePriest P
Semin Oncol; 2007 Jun; 34(3):226-33. PubMed ID: 17560984
[TBL] [Abstract][Full Text] [Related]
9. [Tumor-associated antigen CA-125 in patients with ovarian cancer receiving various combinations of therapy].
Akhmedova SA; Sergeeva NS; Marshutina NV; Mishunina MP; Novikova EG
Vopr Onkol; 2003; 49(1):95-8. PubMed ID: 12715380
[TBL] [Abstract][Full Text] [Related]
10. Advances in the surgical management of ovarian cancer.
Horowitz NS; Duska LR
J Reprod Med; 2005 Jun; 50(6):454-66. PubMed ID: 16050570
[TBL] [Abstract][Full Text] [Related]
11. [Ovarian cancer].
Finnish Gynecological Association
Duodecim; 2001; 117(22):2318-32. PubMed ID: 12183965
[No Abstract] [Full Text] [Related]
12. CA-125: a biomarker put to the test.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1290-1. PubMed ID: 21852262
[No Abstract] [Full Text] [Related]
13. Re: A statement for extensive primary cytoreductive surgery in advanced ovarian cancer.
Nevin J; Luesley D
BJOG; 2008 Nov; 115(12):1586; author reply 1586-7. PubMed ID: 19036008
[No Abstract] [Full Text] [Related]
14. Patterns of care in surgery for ovarian cancer in Europe.
Verleye L; Vergote I; van der Zee AG
Eur J Surg Oncol; 2010 Sep; 36 Suppl 1():S108-14. PubMed ID: 20580524
[TBL] [Abstract][Full Text] [Related]
15. [Surgical treatment for endometriomas].
Dubuisson JB
J Gynecol Obstet Biol Reprod (Paris); 2003 Dec; 32(8 Pt 2):S20-2. PubMed ID: 14968063
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy for ovarian cancer: clarifying the confusion.
Wallach RC
Oncology (Williston Park); 2008 Nov; 22(13):1456; author reply 1456-7. PubMed ID: 19133602
[No Abstract] [Full Text] [Related]
17. An unusual presentation of Stage III ovarian carcinoma.
Noor S; Khan R; Hollingworth A
J Obstet Gynaecol; 2005 Aug; 25(6):619-20. PubMed ID: 16234164
[No Abstract] [Full Text] [Related]
18. Upping the ante in assessing the feasibility of surgical cytoreduction for advanced ovarian cancer: a modified laparoscopic Predictive Index score.
Ramirez PT
Gynecol Oncol; 2015 Oct; 139(1):1-2. PubMed ID: 26411361
[No Abstract] [Full Text] [Related]
19. Development of ovarian cancer surgery quality indicators using a modified Delphi approach.
Gagliardi AR; Fung MF; Langer B; Stern H; Brown AD
Gynecol Oncol; 2005 May; 97(2):446-56. PubMed ID: 15863144
[TBL] [Abstract][Full Text] [Related]
20. Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer.
Chi DS; Schwartz PE
Gynecol Oncol; 2008 Dec; 111(3):391-9. PubMed ID: 19041036
[No Abstract] [Full Text] [Related]
[Next] [New Search]
